Grace Therapeutics, INC Form 4 insider transactions

Grace Therapeutics Director Vimal Kavuru acquired 10,000 stock options with an exercise price of $3.80, vesting through September 2026.

Grace Therapeutics, Inc. Director George Kottayil was granted 10,000 stock options with an exercise price of $3.80, vesting over time.

Grace Therapeutics Director Edward Neugeboren was granted 10,000 stock options with an exercise price of $3.8, vesting over several months.

Grace Therapeutics Director A Brian Davis was granted 10,000 stock options with a $3.8 exercise price, vesting over time.

George Kottayil, a director at Grace Therapeutics, acquired stock options for 10,000 shares at an exercise price of $2.72 on May 9, 2025.

Director Edward Neugeboren of Grace Therapeutics, Inc. reports the acquisition of stock options.

Brian Davis, a director at Grace Therapeutics, acquired stock options for 10,000 shares at an exercise price of $2.72 on May 9, 2025.

Vimal Kavuru, a director at Grace Therapeutics, was granted stock options for 10,000 shares on May 9, 2025, according to a recent SEC filing.

Amresh Kumar, VP of Program Management at Grace Therapeutics, acquires stock options vesting over three years.

R. Loch Macdonald, Chief Medical Officer of Grace Therapeutics, was granted stock options for 40,000 shares on April 14, 2025, according to a Form 4 filing with the SEC.

Robert DelAversano, Principal Financial Officer of Grace Therapeutics, acquired stock options on April 14, 2025, according to a Form 4 filing with the SEC.

Prashant Kohli, CEO of Grace Therapeutics, Inc., was granted stock options to purchase 225,400 shares of common stock at an exercise price of $2.08 on April 14, 2025, according to a Form 4 filing.

Carrie D'Andrea, VP of Clinical Operations at Grace Therapeutics, acquired stock options for 30,000 shares of common stock.

Carrie D'Andrea, VP of Clinical Operations at Acasti Pharma Inc., reports the acquisition of stock options.

Amresh Kumar, VP of Program Management at Acasti Pharma Inc., reports the acquisition of stock options.

Carrie D'Andrea, VP of Program Management at Acasti Pharma Inc., was granted stock options on May 6, 2024.

Amresh Kumar, VP of Clinical Operations at Acasti Pharma Inc., was granted stock options on May 6, 2024.

R. Loch Macdonald, Chief Medical Officer of Acasti Pharma Inc., reports the acquisition of stock options.

Robert J. DelAversano, Principal Financial Officer of Acasti Pharma Inc., was granted stock options for 4,500 Class A Common Shares on May 6, 2024.

Acasti Pharma's CEO, Prashant Kohli, reports the acquisition of stock options.